Camurus
Camurus AB is a Swedish specialty pharmaceutical company that develops and commercializes long-acting injectable medicines based on its proprietary FluidCrystal depot technology, serving patients with opioid dependence, acromegaly, and other severe chronic diseases across Europe, Australia, and the US.
- Company typePublic
- Founded1991
- HeadquartersLund, Sweden
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Camurus does
Camurus AB is a Swedish specialty pharmaceutical company headquartered in Lund that develops and commercializes long-acting injectable medicines for severe and chronic diseases. Its proprietary FluidCrystal technology is a patented lipid-based depot platform that, upon subcutaneous injection, transforms into a liquid crystalline gel to release active substances over days to months via pre-filled syringes or injection pens. The commercial portfolio includes Buvidal (long-acting buprenorphine for opioid dependence, approved in EU/Australia and licensed to Braeburn as Brixadi in the US) and Oczyesa (octreotide SC depot for acromegaly, launched in the EU/UK from November 2025 and filed in the US as Oclaiz).
The company generates revenue through direct specialty sales of approved products across major European markets — supported by wholly-owned subsidiaries in the UK, Germany, Australia, Norway, Finland, Denmark, Austria, Belgium, France, Spain and the US — and through distribution and licensing partnerships that expand geographic reach and monetize the FluidCrystal platform with third-party molecules. Beyond its own products, Camurus pursues a partnered licensing model, most notably with Eli Lilly for long-acting cardiometabolic candidates (GLP-1/GIP/glucagon and amylin receptor agonists) and with Gubra for a long-acting hypoparathyroidism treatment, generating upfronts, milestones and tiered royalties.
FY2025 revenue reached SEK 2,265M (+21% YoY) with profit before tax of SEK 933M (+69% YoY), and FY2026 guidance points to SEK 2.6-2.9B. The pipeline targets indications including acromegaly, gastroenteropancreatic neuroendocrine tumors, polycystic liver disease, hypoparathyroidism, and genetically driven obesity, with a SEK 3.9B cash position at end-Q1 2026 supporting continued investment in organic and partnered R&D.
Camurus firmographics
Firmographics- Name
- Camurus
- Legal name
- Camurus AB
- Website
- https://camurus.com
- Company type
- Public
- Founded year
- 1991
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Camurus AB is a Swedish specialty pharmaceutical company that develops and commercializes long-acting injectable medicines based on its proprietary FluidCrystal depot technology, serving patients with opioid dependence, acromegaly, and other severe chronic diseases across Europe, Australia, and the US.
- Ownership category
- akta.pro rank
Camurus industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where Camurus is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices5 records
Markets served
Camurus business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- Product Sales: Direct product sales of approved pharmaceuticals including Buvidal (opioid dependence) and Oczyesa (acromegaly, EU/UK). Revenue generated through direct commercial operations in European markets and through distribution partners globally.
- Partnership Milestones and Royalties: Upfront payments, development and regulatory milestones, sales-based milestones, and tiered royalties from collaboration agreements with pharmaceutical partners including Eli Lilly for FluidCrystal technology licensing.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Camurus product offering
Product offeringCore offering
Camurus develops, manufactures, and commercializes long-acting injectable medicines based on its proprietary FluidCrystal drug delivery technology for severe and chronic diseases. Approved commercial products include Buvidal (long-acting buprenorphine for opioid dependence) and Oczyesa/Oclaiz (octreotide subcutaneous depot for acromegaly). The company also licenses FluidCrystal to partners such as Eli Lilly and Rhythm Pharmaceuticals for cardiometabolic and obesity indications.
Differentiator
Problem solved
Functional benefit
Brands
- FluidCrystal: Proprietary drug delivery technology platform enabling long-acting release of pharmaceuticals from days to months via subcutaneous injection
- Buvidal
- Oczyesa
- Oclaiz
Products and services
- Buvidal Long-acting injectable buprenorphine based on FluidCrystal technology for the treatment of opioid dependence in adults, providing sustained therapeutic effect and reducing dosing frequency to once weekly or monthly subcutaneous administration. Marketed in Europe and Australia.
- Oczyesa (CAM2029) Octreotide subcutaneous depot for the treatment of acromegaly, based on FluidCrystal technology. Marketed under the brand name Oczyesa in the EU and UK. Designed for once-monthly subcutaneous self-administration via pre-filled injection pen.
- Oclaiz (CAM2029) US brand name for CAM2029 octreotide subcutaneous depot for the treatment of acromegaly, identical formulation to Oczyesa sold in the EU/UK. Pending FDA approval.
Quantifiable outcome
- Approximately 5-fold increase in dose-adjusted plasma exposure vs. current approved long-acting intramuscular octreotide
- +3 more outcomes
Companies that use Camurus
Customer profileSegments3 records
Ideal customer profiles1 record
Camurus technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Camurus partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and major.
- Eli LillycoreEli Lilly expanded its collaboration and license agreement with Camurus to include amylin receptor agonists in addition to dual and triple GLP-1/GIP/glucagon receptor agonists. The expanded agreement covers up to four proprietary Lilly drug compounds across three compound classes. Camurus is eligible for up to $290 million in development and regulatory milestones plus $580 million in sales-based milestones, plus tiered mid-single digit royalties on product sales. A $5 million initial payment was triggered by the option exercise.
- GubracoreExclusive collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism combining Gubra's PTH analogue with Camurus' FluidCrystal technology to enable extended, patient-friendly dosing.
- BraeburnmajorRights to Brixadi long-acting buprenorphine for treatment of opioid dependence in North America. Brixadi is approved in the USA for opioid use disorder treatment.
- Rhythm PharmaceuticalsmajorGlobal rights to CAM4072, a weekly formulation of setmelanotide based on FluidCrystal technology, for treatment of genetically driven obesity diseases.
- NewBridge PharmaceuticalsmajorDistribution rights to Buvidal (CAM2038) in twelve countries in the Middle East and North Africa (MENA) region for treatment of opioid dependence.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Camurus competitors and assessment
Company assessmentBroad incumbents
- Novo Nordisk: Global leader in GLP-1/diabetes/obesity with deep cardiometabolic pipeline. Comparable given Eli Lilly's amylin/GLP-1 expansion with Camurus targets the same therapeutic class as Novo's pipeline, and Novo is the prior employer of Camurus's new CCDO.
- Teva Pharmaceutical Industries: Large specialty/generic pharma with broader portfolio including CNS and rare disease assets, plus drug delivery capabilities. Comparable as a broader portfolio player competing in adjacent specialty categories.
- Ferring Pharmaceuticals: Privately-held specialty pharma focused on reproductive health, urology, and gastroenterology with strong long-acting injectable expertise (including octreotide franchise competing with Camurus's Oczyesa).
- Recordati S.p.A. European specialty pharma with established rare disease and endocrinology franchises. Comparable business model serving similar specialist prescriber base via European commercial infrastructure.
Emerging players
- Halozyme Therapeutics: Drug delivery platform company with ENHANZE technology licensed to multiple large pharma partners. Comparable business model of monetizing a proprietary delivery platform through partnerships and royalties across multiple therapeutic areas.
- Ascendis Pharma: Specialty pharma with TransCon technology platform enabling long-acting prodrug injectables for rare endocrine diseases including acromegaly. Highly comparable technology-platform business model targeting overlapping patient populations.
Direct peers
- Braeburn Pharmaceuticals: Camurus's own channel partner for Brixadi (long-acting buprenorphine for opioid use disorder) in North America. Direct competitor in the same long-acting depot buprenorphine category with similar delivery dynamics.
- Indivior PLC: Direct competitor in opioid dependence treatment with Sublocade (long-acting buprenorphine) and Suboxone, the leading therapy franchise in this market. Highly comparable given overlapping patient population, mechanism, and regulatory pathway.
- Rhythm Pharmaceuticals: Camurus's partner for CAM4072 (weekly setmelanotide using FluidCrystal) and a developer of rare endocrine/genetic obesity therapies. Direct overlap in rare endocrinology and ongoing collaboration relationship.
Regional players
- Hikma Pharmaceuticals: Specialty/generic pharma with strong European and MENA presence, including specialty injectable products. Comparable geographic footprint especially given Camurus's NewBridge MENA partnership.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Camurus social profiles
Digital presenceCamurus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Camurus leadership team
Management profileNumber of profiles
Profiles6 records
Camurus subsidiaries and ownership
Company hierarchySubsidiaries9 records
Camurus funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Camurus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Camurus
What does Camurus do?
Camurus develops, manufactures, and commercializes long-acting injectable medicines based on its proprietary FluidCrystal drug delivery technology for severe and chronic diseases. Approved commercial products include Buvidal (long-acting buprenorphine for opioid dependence) and Oczyesa/Oclaiz (octreotide subcutaneous depot for acromegaly). The company also licenses FluidCrystal to partners such as Eli Lilly and Rhythm Pharmaceuticals for cardiometabolic and obesity indications.
Is Camurus a public or private company?
Camurus is a public company. It is classified as public and is currently operating.
When was Camurus founded?
Camurus was founded in 1991. It employs 251 to 500 people.
Where is Camurus based?
Camurus is headquartered in Lund, Sweden, in the Europe region.
How does Camurus make money?
Two revenue lines are on record. Product Sales are the primary driver. The others are partnership Milestones and Royalties.
Who are Camurus's main competitors?
Broad incumbents on record are Novo Nordisk, Teva Pharmaceutical Industries, Ferring Pharmaceuticals and Recordati S.p.A.. Emerging players are Halozyme Therapeutics and Ascendis Pharma. Direct peers are Braeburn Pharmaceuticals, Indivior PLC and Rhythm Pharmaceuticals. Hikma Pharmaceuticals is listed as a regional player.
Does Camurus have an API?
No public API is recorded for Camurus.
What industry is Camurus in?
Camurus's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.